BioWorld MedTech

Dec. 8, 2016

Abbott ready to bolt on Alere based on 'damaging business developments'

After nearly 10 months of waffling on a $5.8 billion decision, Abbott Laboratories might have spotted an emergency exit from its contract to buy Alere Inc. Read More

MIT team reduces beta amyloid plaques in mice using light therapy

Cures Act sails through Senate in 94-5 landslide

AdvaMed's Trunzo says least burdensome standard revived

EU sliding toward a compliance cliff as regulations advance

Attorney says outcome of hearing on CRISPR patents tough to predict

Abiomed Impella CP gets green light for high-risk PCI treatment

Appointments and advancements

Product briefs

Financings

Other news to note

MDD's Orthopedics Extra

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

Other news to note for July 22, 2026

BioWorld

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...

GSK’s newly acquired Jideytro wins FDA nod in NSCLC

BioWorld

About a week after closing its $10.6 billion acquisition of Nuvalent Inc., GSK plc has reaped the first reward, announcing U.S. FDA approval of zidesamtinib in...